首页 > 最新文献

American journal of therapeutics最新文献

英文 中文
Tofacitinib-Associated Demyelination and Bullous Pemphigoid. 托法替尼相关脱髓鞘和大疱性类天疱疮
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-29 DOI: 10.1097/MJT.0000000000001833
Ting Su, Yuzhen Liu, Shanshan Lu, Wei Zhang, Yan Lu, Zhiqiang Yin
{"title":"Tofacitinib-Associated Demyelination and Bullous Pemphigoid.","authors":"Ting Su, Yuzhen Liu, Shanshan Lu, Wei Zhang, Yan Lu, Zhiqiang Yin","doi":"10.1097/MJT.0000000000001833","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001833","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Treatment of Psoriasis With Apremilast in a Kidney Transplant Recipient. 用阿普司特成功治疗一名肾移植受者的银屑病
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-25 DOI: 10.1097/MJT.0000000000001825
ChaoJing Zhou, YuFei Wang, YiYun Hou, JiLiang Lu, DongHong Sun, ZhiQiang Yin
{"title":"Successful Treatment of Psoriasis With Apremilast in a Kidney Transplant Recipient.","authors":"ChaoJing Zhou, YuFei Wang, YiYun Hou, JiLiang Lu, DongHong Sun, ZhiQiang Yin","doi":"10.1097/MJT.0000000000001825","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001825","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted Therapy Outcomes in Hidradenitis Suppurativa: A Systematic Review. 化脓性扁桃体炎的靶向治疗效果:系统回顾
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-25 DOI: 10.1097/MJT.0000000000001830
Chenxingyue Zhang, Xinyi Dai, Zhiqiang Yin
{"title":"Targeted Therapy Outcomes in Hidradenitis Suppurativa: A Systematic Review.","authors":"Chenxingyue Zhang, Xinyi Dai, Zhiqiang Yin","doi":"10.1097/MJT.0000000000001830","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001830","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Treatment of Mexiletine-Induced Methylprednisolone-Resistant DRESS Syndrome With TNF-α Inhibitor. TNF-α 抑制剂成功治疗甲泼尼龙耐药的美西律汀诱发 DRESS 综合征
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-25 DOI: 10.1097/MJT.0000000000001824
Chengzhong Zhang, Xuechen Cao, Ting Su, Jiping Xia, Meihua Zhang, Zhiqiang Yin, Yan Lu
{"title":"Successful Treatment of Mexiletine-Induced Methylprednisolone-Resistant DRESS Syndrome With TNF-α Inhibitor.","authors":"Chengzhong Zhang, Xuechen Cao, Ting Su, Jiping Xia, Meihua Zhang, Zhiqiang Yin, Yan Lu","doi":"10.1097/MJT.0000000000001824","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001824","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Meropenem-Associated Delirium. 美罗培南相关性谵妄。
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-22 DOI: 10.1097/MJT.0000000000001774
Xin-Liang Yang, Ye-Jun Chen, Wei Ou, Xiao-Hua Xie
{"title":"Meropenem-Associated Delirium.","authors":"Xin-Liang Yang, Ye-Jun Chen, Wei Ou, Xiao-Hua Xie","doi":"10.1097/MJT.0000000000001774","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001774","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transplanted Kidney Failure and Bleeding Caused by Combination of Tacrolimus, Paxlovid, and Dalteparin. 他克莫司、Paxlovid 和 Dalteparin 联合用药导致移植肾衰竭和出血。
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-22 DOI: 10.1097/MJT.0000000000001764
Xin-Liang Yang, Ye-Jun Chen, Wei Ou, Xiao-Hua Xie
{"title":"Transplanted Kidney Failure and Bleeding Caused by Combination of Tacrolimus, Paxlovid, and Dalteparin.","authors":"Xin-Liang Yang, Ye-Jun Chen, Wei Ou, Xiao-Hua Xie","doi":"10.1097/MJT.0000000000001764","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001764","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of Inhibitors of the Proximal Pathway of the Complement System in Paroxysmal Nocturnal Hemoglobinuria: A Meta-analysis of Randomized Controlled Trials. 补体系统近端通路抑制剂对阵发性夜间血红蛋白尿症的疗效和安全性:随机对照试验的 Meta 分析》。
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-22 DOI: 10.1097/MJT.0000000000001837
Milene Vitória Sampaio Sobral, Isac Ribeiro Moulaz, Victor Gonçalves Soares, Rafaela da Cunha Pirolla, Lucas Cael Azevedo Ramos Bendaham, Hilária Saugo Faria, Clara de Andrade Pontual Peres, Lubna Al-Sharif, Rebeca Carvalho Bressa
{"title":"Efficacy and Safety of Inhibitors of the Proximal Pathway of the Complement System in Paroxysmal Nocturnal Hemoglobinuria: A Meta-analysis of Randomized Controlled Trials.","authors":"Milene Vitória Sampaio Sobral, Isac Ribeiro Moulaz, Victor Gonçalves Soares, Rafaela da Cunha Pirolla, Lucas Cael Azevedo Ramos Bendaham, Hilária Saugo Faria, Clara de Andrade Pontual Peres, Lubna Al-Sharif, Rebeca Carvalho Bressa","doi":"10.1097/MJT.0000000000001837","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001837","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Characteristics and Prognosis of 39 Cases of Retinoblastoma With Optic Nerve Stump Involvement. 39例视神经残端受累视网膜母细胞瘤的临床特征和预后
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-18 DOI: 10.1097/MJT.0000000000001794
Yi-Zhuo Wang, Hui-Min Hu, Yi Zhang, Ji-Tong Shi, Jian-Min Ma, Wei-Ling Zhang, Hua-Li Gu, Yan Zhou, Dong-Sheng Huang
{"title":"Clinical Characteristics and Prognosis of 39 Cases of Retinoblastoma With Optic Nerve Stump Involvement.","authors":"Yi-Zhuo Wang, Hui-Min Hu, Yi Zhang, Ji-Tong Shi, Jian-Min Ma, Wei-Ling Zhang, Hua-Li Gu, Yan Zhou, Dong-Sheng Huang","doi":"10.1097/MJT.0000000000001794","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001794","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of Ibrutinib as Monotherapy or Combination Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): A Systematic Review and Meta-analysis. 伊布替尼作为单药或联合疗法治疗复发/难治性弥漫大B细胞淋巴瘤(R/R DLBCL)的疗效和安全性:系统综述与元分析》。
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-16 DOI: 10.1097/MJT.0000000000001831
Yin Li, Chunfan Li, Kebing Lv, Shixuan Wang, Fei Li

Background: Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease group. Ibrutinib's monotherapy or combination therapy is effective in relapsed/refractory (R/R) DLBCL. However, the treatment response in R/R DLBCL varies from 15% to 90% with different regimens, and the tolerance remains controversial.

Areas of uncertainty: The efficacy and safety of ibrutinib monotherapy or combination therapy in patients with R/R DLBCL remain uncertain.

Data sources: The PubMed, CBM, MEDLINE, Cochrane Library, and Embase databases were searched from their inception to July 2021.

Therapeutic advances: The total complete remission rate (CRR) and overall response rate in R/R DLBCL patients treated with ibrutinib were 26% and 49%, respectively. The CRR of ibrutinib combination therapy was significantly higher than the ibrutinib monotherapy (45% vs. 19%). Moreover, the CRR of patients was 40% in double expressing lymphoma, 35% in central nervous system lymphoma, and 33% in nongerminal center B-cell-like (non-GCB) DLBCL, which was higher than the 8% in those with the GCB subtype. The pooled median PFS and overall survival were 5.57 and 10.17 months, respectively. GCB-DLBCL had the worst overall survival (5.1 months). Nevertheless, we found that combination regimens had no survival advantage compared with monotherapy (P > 0.05), indicating that combination therapy was only a transitional treatment and bridge for chimeric antigen receptor T cells or other treatments. Moreover, 12% of patients on ibrutinib combination therapy had ≥grade 3 adverse events compared with 9% on ibrutinib monotherapy.

Conclusions: Ibrutinib monotherapy or combination therapy was safe and effective in treating R/R DLBCL with tolerable adverse reactions.

背景:弥漫大 B 细胞淋巴瘤(DLBCL弥漫大B细胞淋巴瘤(DLBCL)是一种高度异质性疾病。伊布替尼单药或联合疗法对复发/难治(R/R)DLBCL有效。然而,不同方案对R/R DLBCL的治疗反应从15%到90%不等,耐受性仍存在争议:伊布替尼单药治疗或联合治疗对R/R DLBCL患者的疗效和安全性仍不确定:数据来源:对PubMed、CBM、MEDLINE、Cochrane Library和Embase数据库从开始到2021年7月的数据进行了检索:接受伊布替尼治疗的R/R DLBCL患者的总完全缓解率(CRR)和总反应率分别为26%和49%。伊布替尼联合疗法的CRR明显高于伊布替尼单药疗法(45%对19%)。此外,双表达淋巴瘤患者的CRR为40%,中枢神经系统淋巴瘤患者的CRR为35%,非皮层中心B细胞样(非GCB)DLBCL患者的CRR为33%,均高于GCB亚型患者的8%。汇总的中位生存期和总生存期分别为5.57个月和10.17个月。GCB-DLBCL的总生存期最短(5.1个月)。然而,我们发现联合疗法与单一疗法相比没有生存优势(P > 0.05),这表明联合疗法只是一种过渡性疗法,是嵌合抗原受体T细胞或其他疗法的桥梁。此外,与接受伊布替尼单药治疗的9%患者相比,接受伊布替尼联合治疗的12%患者出现了≥3级不良事件:伊布替尼单药或联合疗法治疗R/R DLBCL安全有效,不良反应可耐受。
{"title":"Efficacy and Safety of Ibrutinib as Monotherapy or Combination Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): A Systematic Review and Meta-analysis.","authors":"Yin Li, Chunfan Li, Kebing Lv, Shixuan Wang, Fei Li","doi":"10.1097/MJT.0000000000001831","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001831","url":null,"abstract":"<p><strong>Background: </strong>Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease group. Ibrutinib's monotherapy or combination therapy is effective in relapsed/refractory (R/R) DLBCL. However, the treatment response in R/R DLBCL varies from 15% to 90% with different regimens, and the tolerance remains controversial.</p><p><strong>Areas of uncertainty: </strong>The efficacy and safety of ibrutinib monotherapy or combination therapy in patients with R/R DLBCL remain uncertain.</p><p><strong>Data sources: </strong>The PubMed, CBM, MEDLINE, Cochrane Library, and Embase databases were searched from their inception to July 2021.</p><p><strong>Therapeutic advances: </strong>The total complete remission rate (CRR) and overall response rate in R/R DLBCL patients treated with ibrutinib were 26% and 49%, respectively. The CRR of ibrutinib combination therapy was significantly higher than the ibrutinib monotherapy (45% vs. 19%). Moreover, the CRR of patients was 40% in double expressing lymphoma, 35% in central nervous system lymphoma, and 33% in nongerminal center B-cell-like (non-GCB) DLBCL, which was higher than the 8% in those with the GCB subtype. The pooled median PFS and overall survival were 5.57 and 10.17 months, respectively. GCB-DLBCL had the worst overall survival (5.1 months). Nevertheless, we found that combination regimens had no survival advantage compared with monotherapy (P > 0.05), indicating that combination therapy was only a transitional treatment and bridge for chimeric antigen receptor T cells or other treatments. Moreover, 12% of patients on ibrutinib combination therapy had ≥grade 3 adverse events compared with 9% on ibrutinib monotherapy.</p><p><strong>Conclusions: </strong>Ibrutinib monotherapy or combination therapy was safe and effective in treating R/R DLBCL with tolerable adverse reactions.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mesalazine-Associated Agranulocytosis. 美沙拉嗪相关粒细胞减少症
IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-16 DOI: 10.1097/MJT.0000000000001832
You-Jiao Chen, Dan-Ni Luo, Zi-Meng Wan, Feng Chen
{"title":"Mesalazine-Associated Agranulocytosis.","authors":"You-Jiao Chen, Dan-Ni Luo, Zi-Meng Wan, Feng Chen","doi":"10.1097/MJT.0000000000001832","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001832","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American journal of therapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1